Portage Biotech Inc PRTG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRTG is a good fit for your portfolio.
News
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
-
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Portage Biotech Announces $6.0 Million Registered Direct Offering
-
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
-
Portage Biotech in Keytruda Collaboration With Merck
-
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
Trading Information
- Previous Close Price
- $1.33
- Day Range
- $1.31–1.40
- 52-Week Range
- $1.21–7.67
- Bid/Ask
- $1.33 / $1.35
- Market Cap
- $26.69 Mil
- Volume/Avg
- 7,282 / 27,684
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.portagebiotech.com
Valuation
|
Metric
|
PRTG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PRTG
Financial Strength
|
Metric
|
PRTG
|
|---|---|
Quick Ratio | 1.25 |
Current Ratio | 2.00 |
Interest Coverage | −7,945.31 |
Quick Ratio
PRTG
Profitability
|
Metric
|
PRTG
|
|---|---|
Return on Assets (Normalized) | −6.83% |
Return on Equity (Normalized) | −10.67% |
Return on Invested Capital (Normalized) | −8.93% |
Return on Assets
PRTG
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jxzdn | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jjzzbkj | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lrkltq | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Frnbyt | $40.2 Bil | |
MRNA
| Moderna Inc | Rzg | $29.6 Bil | |
ARGX
| argenx SE ADR | Jfyd | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Mtwt | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yrmlf | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bmclxp | $17.2 Bil | |
INCY
| Incyte Corp | Pmrhhzh | $12.2 Bil |